217 related articles for article (PubMed ID: 3016942)
1. Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor, RA 233.
Dawicki DD; Agarwal KC; Parks RE
Thromb Res; 1986 Jul; 43(2):161-75. PubMed ID: 3016942
[TBL] [Abstract][Full Text] [Related]
2. Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine.
Dawicki DD; Agarwal KC; Parks RE
Biochem Pharmacol; 1985 Nov; 34(22):3965-72. PubMed ID: 4062970
[TBL] [Abstract][Full Text] [Related]
3. Role of plasma adenosine in the antiplatelet action of HL 725, a potent inhibitor of cAMP phosphodiesterase: species differences.
Agarwal KC; Buckley RS; Parks RE
Thromb Res; 1987 Jul; 47(2):191-200. PubMed ID: 2821650
[TBL] [Abstract][Full Text] [Related]
4. Significance of plasma adenosine in the antiplatelet activity of forskolin: potentiation by dipyridamole and dilazep.
Agarwal KC; Zielinski BA; Maitra RS
Thromb Haemost; 1989 Feb; 61(1):106-10. PubMed ID: 2749584
[TBL] [Abstract][Full Text] [Related]
5. Adenosine metabolism in human whole blood. Effects of nucleoside transport inhibitors and phosphate concentration.
Dawicki DD; Agarwal KC; Parks RE
Biochem Pharmacol; 1988 Feb; 37(4):621-6. PubMed ID: 3342099
[TBL] [Abstract][Full Text] [Related]
6. Role of nucleoside transport in drug action. The adenosine deaminase inhibitor, deoxycoformycin, and the antiplatelet drugs, dipyridamole and dilazep.
Parks RE; Dawicki DD; Agarwal KC; Chen SF; Stoeckler JD
Ann N Y Acad Sci; 1985; 451():188-203. PubMed ID: 3878117
[No Abstract] [Full Text] [Related]
7. Effect of dipyridamole-like compound (R-E 244) on aggregation and cyclic AMP accumulation in human platelets.
Söderbäck U; Sollevi A
Thromb Res; 1991 Nov; 64(3):355-62. PubMed ID: 1666697
[TBL] [Abstract][Full Text] [Related]
8. Relative potencies of dipyridamole and related agents as inhibitors of cyclic nucleotide phosphodiesterases: possible explanation of mechansim of inhibition of platelet function.
McElroy FA; Philip RB
Life Sci; 1975 Nov; 17(9):1479-93. PubMed ID: 173959
[No Abstract] [Full Text] [Related]
9. Cilostazol and dipyridamole synergistically inhibit human platelet aggregation.
Liu Y; Cone J; Le SN; Fong M; Tao L; Shoaf SE; Bricmont P; Czerwiec FS; Kambayashi J; Yoshitake M; Sun B
J Cardiovasc Pharmacol; 2004 Aug; 44(2):266-73. PubMed ID: 15243309
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro.
Azuma H; Takashima Y; Ishikawa M; Yamakado T
Jpn J Pharmacol; 1984 Feb; 34(2):159-70. PubMed ID: 6205194
[TBL] [Abstract][Full Text] [Related]
11. Nucleoside transport inhibition and fMLP-stimulated whole blood luminescence.
Ver Donck KL; Verheyen WJ; Van Belle H
J Mol Cell Cardiol; 1991 Jul; 23(7):783-5. PubMed ID: 1791629
[TBL] [Abstract][Full Text] [Related]
12. Species differences in sensitivity of nucleoside transport in erythrocytes and cultured cells to inhibition by nitrobenzylthioinosine, dipyridamole, dilazep and lidoflazine.
Plagemann PG; Woffendin C
Biochim Biophys Acta; 1988 Apr; 969(1):1-8. PubMed ID: 3349106
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of the pyrimido-pyrimidine derivatives, dipyridamole and mopidamol, on platelet and vascular cyclooxygenase activity.
De La Cruz JP; Ortega G; Sánchez de la Cuesta F
Biochem Pharmacol; 1994 Jan; 47(2):209-15. PubMed ID: 8304965
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human platelet cyclic AMP phosphodiesterase and of platelet aggregation by a hemisynthetic flavonoid, amentoflavone hexaacetate.
Beretz A; Briançon-Scheid F; Stierlé A; Corre G; Anton R; Cazenave JP
Biochem Pharmacol; 1986 Jan; 35(2):257-62. PubMed ID: 3002388
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of nucleoside and nucleobase transport and nitrobenzylthioinosine binding by dilazep and hexobendine.
Plagemann PG; Kraupp M
Biochem Pharmacol; 1986 Aug; 35(15):2559-67. PubMed ID: 3741459
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the abilities of nitrobenzylthioinosine, dilazep, and dipyridamole to protect human hematopoietic cells from 7-deazaadenosine (tubercidin).
Cass CE; King KM; Montaño JT; Janowska-Wieczorek A
Cancer Res; 1992 Nov; 52(21):5879-86. PubMed ID: 1394215
[TBL] [Abstract][Full Text] [Related]
17. Prevention of human pancreatic cancer cell-induced hepatic metastasis in nude mice by dipyridamole and its analog RA-233.
Tzanakakis GN; Agarwal KC; Vezeridis MP
Cancer; 1993 Apr; 71(8):2466-71. PubMed ID: 8453569
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity.
Gresele P; Arnout J; Deckmyn H; Vermylen J
Thromb Haemost; 1986 Feb; 55(1):12-8. PubMed ID: 3704998
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of glucose uptake in murine cardiomyocyte cell line HL-1 by cardioprotective drugs dilazep and dipyridamole.
Shuralyova I; Tajmir P; Bilan PJ; Sweeney G; Coe IR
Am J Physiol Heart Circ Physiol; 2004 Feb; 286(2):H627-32. PubMed ID: 14551048
[TBL] [Abstract][Full Text] [Related]
20. Characterization of inhibitor-sensitive and -resistant adenosine transporters in cultured human fetal astrocytes.
Gu JG; Nath A; Geiger JD
J Neurochem; 1996 Sep; 67(3):972-7. PubMed ID: 8752102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
